Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Gastrointestinal 2Head & Neck 1Genitourinary 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 341Ovarian Neoplasms 177Lung Neoplasms 171Breast Neoplasms 118Fallopian Tube Neoplasms 87Neoplasms 79Carcinoma, Ovarian Epithelial 69Squamous Cell Carcinoma of Head and Neck 51Small Cell Lung Carcinoma 49Triple Negative Breast Neoplasms 41Adenocarcinoma of Lung 41Head and Neck Neoplasms 40Neoplasm Metastasis 37Neuroblastoma 34Central Nervous System Neoplasms 33Endometrial Neoplasms 28Esophageal Neoplasms 27Carcinoma 27Brain Neoplasms 27Lymphoma 26Recurrence 25Lymphoma, Large B-Cell, Diffuse 25Urinary Bladder Neoplasms 24Parkinson Disease 4, Autosomal Dominant Lewy Body 24Adenocarcinoma, Bronchiolo-Alveolar 23Testicular Neoplasms 22Astrocytoma 22Melanoma 19Uterine Cervical Neoplasms 18Prostatic Neoplasms 18

Interventions

Gemcitabine 8130-nm albumin-bound paclitaxel 5Albumin-Bound Paclitaxel 4napabucasin 2Oxaliplatin 2MK-4721 2Leucovorin 2Fluorouracil 2Carboplatin 2tremelimumab 1irinotecan sucrosofate 1ensituximab 1durvalumab 1contrast agent BR1 1cc-486 1Taxes 1Practice Guidelines as Topic 1Pancreaticoduodenectomy 1Paclitaxel 1PEGPH20 1Lead 1Irinotecan 1Enoxaparin 1EC regimen 1Drug Therapy 1Dexamethasone 1Cisplatin 1CP protocol 1Azacitidine 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Carcinoma, Pancreatic Ductal × Carboplatin × Clear all
NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

AstraZeneca

Phase 1 Completed
32 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01478685 2019-11-12

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Celgene

Phase 1 Completed
169 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Tumor Virus Infections, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡